See more : CHTC Fong’s International Company Limited (0641.HK) Income Statement Analysis – Financial Results
Complete financial analysis of Gilead Sciences, Inc. (GILD) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Gilead Sciences, Inc., a leading company in the Drug Manufacturers – General industry within the Healthcare sector.
- Shenzhen Tagen Group Co., Ltd. (000090.SZ) Income Statement Analysis – Financial Results
- Tianjin Lisheng Pharmaceutical Co.,Ltd. (002393.SZ) Income Statement Analysis – Financial Results
- iMining Technologies Inc. (IBKKF) Income Statement Analysis – Financial Results
- First Quantum Minerals Ltd. (FQVLF) Income Statement Analysis – Financial Results
- Ishii Food Co., Ltd. (2894.T) Income Statement Analysis – Financial Results
Gilead Sciences, Inc. (GILD)
About Gilead Sciences, Inc.
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Gadeta B.V.; Bristol-Myers Squibb Company; Dragonfly Therapeutics, Inc.; and Merck & Co, Inc. The company was incorporated in 1987 and is headquartered in Foster City, California.
Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 | 1992 | 1991 | 1990 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | 27.12B | 27.28B | 27.31B | 24.69B | 22.45B | 22.13B | 26.11B | 30.39B | 32.64B | 24.89B | 11.20B | 9.70B | 8.39B | 7.95B | 7.01B | 5.34B | 4.23B | 3.03B | 2.03B | 1.32B | 867.86M | 466.79M | 233.77M | 195.56M | 169.00M | 32.60M | 40.00M | 33.40M | 2.70M | 4.10M | 4.20M | 2.80M | 1.30M |
Cost of Revenue | 6.50B | 5.66B | 6.60B | 4.57B | 4.68B | 4.85B | 4.37B | 4.26B | 4.01B | 3.79B | 2.86B | 2.47B | 2.12B | 1.87B | 1.60B | 1.13B | 768.77M | 433.32M | 260.33M | 166.59M | 112.69M | 69.72M | 43.76M | 21.50M | 16.90M | -2.20M | -1.80M | -3.60M | -3.20M | -2.80M | -1.70M | -1.00M | -800.00K |
Gross Profit | 20.62B | 21.62B | 20.70B | 20.12B | 17.77B | 17.27B | 21.74B | 26.13B | 28.63B | 21.10B | 8.34B | 7.23B | 6.26B | 6.08B | 5.42B | 4.21B | 3.46B | 2.59B | 1.77B | 1.16B | 755.17M | 397.07M | 190.01M | 174.05M | 152.10M | 34.80M | 41.80M | 37.00M | 5.90M | 6.90M | 5.90M | 3.80M | 2.10M |
Gross Profit Ratio | 76.04% | 79.26% | 75.82% | 81.48% | 79.18% | 78.07% | 83.26% | 85.98% | 87.73% | 84.78% | 74.48% | 74.53% | 74.67% | 76.48% | 77.24% | 78.87% | 81.83% | 85.68% | 87.17% | 87.42% | 87.02% | 85.06% | 81.28% | 89.00% | 90.00% | 106.75% | 104.50% | 110.78% | 218.52% | 168.29% | 140.48% | 135.71% | 161.54% |
Research & Development | 6.92B | 4.98B | 5.36B | 5.04B | 9.11B | 5.02B | 3.73B | 5.10B | 3.01B | 2.85B | 2.12B | 1.76B | 1.23B | 1.07B | 939.92M | 721.77M | 591.03M | 383.86M | 277.72M | 223.55M | 164.87M | 134.76M | 185.55M | 131.57M | 112.90M | 75.30M | 59.20M | 41.90M | 0.00 | 26.00M | 0.00 | 0.00 | 0.00 |
General & Administrative | 5.26B | 4.90B | 4.51B | 4.36B | 3.60B | 4.06B | 3.88B | 3.40B | 3.43B | 2.98B | 1.70B | 1.46B | 1.24B | 1.04B | 946.69M | 797.34M | 705.74M | 573.66M | 379.25M | 302.79M | 250.16M | 181.30M | 125.14M | 82.79M | 78.30M | 31.00M | 25.50M | 26.70M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Selling & Marketing | 826.00M | 778.00M | 735.00M | 795.00M | 784.00M | 587.00M | 600.00M | 618.00M | 601.00M | 393.00M | 216.00M | 160.00M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A | 6.09B | 5.67B | 5.25B | 5.15B | 4.38B | 4.06B | 3.88B | 3.40B | 3.43B | 2.98B | 1.70B | 1.46B | 1.24B | 1.04B | 946.69M | 797.34M | 705.74M | 573.66M | 379.25M | 302.79M | 250.16M | 181.30M | 125.14M | 82.79M | 78.30M | 31.00M | 25.50M | 26.70M | 34.70M | 7.60M | 22.40M | 9.10M | 6.10M |
Other Expenses | 0.00 | -581.00M | -639.00M | -1.42B | 1.87B | 676.00M | 523.00M | 428.00M | 154.00M | 3.00M | -8.89M | -37.28M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 10.22M | 0.00 | 0.00 | 12.01M | 12.60M | 2.80M | 3.00M | 4.50M | 3.20M | 2.80M | 1.70M | 1.00M | 800.00K |
Operating Expenses | 13.67B | 10.65B | 10.61B | 10.19B | 13.49B | 9.07B | 7.61B | 8.50B | 6.44B | 5.84B | 3.82B | 3.22B | 2.47B | 2.12B | 1.89B | 1.53B | 1.30B | 957.52M | 656.97M | 526.35M | 425.25M | 316.06M | 310.69M | 226.37M | 203.80M | 109.10M | 87.70M | 73.10M | 37.90M | 36.40M | 24.10M | 10.10M | 6.90M |
Cost & Expenses | 19.69B | 16.31B | 17.21B | 14.76B | 18.16B | 13.93B | 11.98B | 12.76B | 10.45B | 9.63B | 6.68B | 5.69B | 4.60B | 3.99B | 3.48B | 2.66B | 2.07B | 1.39B | 917.30M | 692.93M | 537.94M | 385.78M | 354.46M | 247.87M | 220.70M | 106.90M | 85.90M | 69.50M | 34.70M | 33.60M | 22.40M | 9.10M | 6.10M |
Interest Income | 0.00 | 935.00M | 1.00B | 984.00M | 995.00M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 66.58M | 60.29M | 42.40M | 59.40M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Interest Expense | 944.00M | 935.00M | 1.00B | 984.00M | 995.00M | 1.08B | 1.12B | 964.00M | 688.00M | 412.00M | 306.89M | 360.92M | 205.42M | 108.96M | 69.66M | 12.10M | 0.00 | 4.67B | 0.00 | 0.00 | 996.28M | 23.66M | 0.00 | 6.12M | 37.70M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Depreciation & Amortization | 2.69B | 2.10B | 2.05B | 1.48B | 1.40B | 1.43B | 1.29B | 1.16B | 1.10B | 1.05B | 344.70M | 278.21M | 302.23M | 265.48M | 212.94M | 102.47M | 51.28M | 47.28M | 35.78M | 24.41M | 20.86M | 14.43M | 14.69M | 12.01M | 12.60M | 2.80M | 3.00M | 4.50M | 3.20M | 2.80M | 1.70M | 1.00M | 800.00K |
EBITDA | 10.50B | 8.85B | 11.33B | 4.13B | 7.56B | 10.31B | 15.93B | 19.22B | 23.45B | 16.32B | 4.86B | 4.25B | 4.16B | 4.29B | 3.78B | 2.84B | 2.22B | -576.83M | 1.15B | 688.18M | 350.78M | 81.01M | -106.00M | -40.31M | -39.10M | -65.10M | -56.90M | -31.60M | -28.80M | -31.30M | -16.50M | -5.30M | -4.00M |
EBITDA Ratio | 38.71% | 38.10% | 34.63% | 34.46% | 27.42% | 40.11% | 56.10% | 59.43% | 68.47% | 61.34% | 40.31% | 40.95% | 45.99% | 50.60% | 50.94% | 51.47% | 52.38% | 134.71% | 56.54% | 48.54% | 97.90% | 23.88% | -116.58% | -19.15% | -9.05% | -275.77% | -153.00% | -139.52% | -1,259.26% | -753.66% | -495.24% | -257.14% | -369.23% |
Operating Income | 7.61B | 7.33B | 7.41B | 7.03B | 4.29B | 8.20B | 14.12B | 17.63B | 22.19B | 15.27B | 4.52B | 4.01B | 3.79B | 3.96B | 3.53B | 2.68B | 2.16B | -758.75M | 1.11B | 631.69M | -158.68M | 81.01M | -120.69M | -52.32M | -51.70M | -74.30M | -45.90M | -36.10M | -32.00M | -29.50M | -18.20M | -6.30M | -4.80M |
Operating Income Ratio | 28.05% | 26.87% | 27.12% | 28.47% | 19.10% | 37.06% | 54.10% | 58.02% | 68.00% | 61.33% | 40.39% | 41.33% | 45.20% | 49.84% | 50.34% | 50.20% | 51.17% | -25.07% | 54.78% | 47.69% | -18.28% | 17.35% | -51.63% | -26.75% | -30.59% | -227.91% | -114.75% | -108.08% | -1,185.19% | -719.51% | -433.33% | -225.00% | -369.23% |
Total Other Income/Expenses | -746.00M | -1.52B | 872.00M | -2.40B | 873.00M | -401.00M | -595.00M | -536.00M | -534.00M | -409.00M | -315.78M | -398.20M | -138.84M | -48.67M | -27.27M | -5.84M | 105.83M | 120.55M | 50.69M | 24.73M | -8.86M | -7.61M | 178.14M | 10.41M | -13.90M | 22.40M | -500.00K | 15.00M | 5.20M | 9.90M | 4.30M | 1.90M | 800.00K |
Income Before Tax | 6.86B | 5.81B | 8.28B | 1.67B | 5.16B | 7.80B | 13.53B | 17.10B | 21.66B | 14.86B | 4.21B | 3.61B | 3.65B | 3.91B | 3.50B | 2.73B | 2.27B | -638.21M | 1.16B | 656.42M | -167.53M | 73.40M | 57.45M | -41.91M | -65.60M | -55.90M | -27.60M | -21.10M | -26.80M | -25.30M | -13.90M | -4.40M | -4.00M |
Income Before Tax Ratio | 25.30% | 21.31% | 30.32% | 6.76% | 22.99% | 35.25% | 51.82% | 56.26% | 66.36% | 59.69% | 37.57% | 37.23% | 43.54% | 49.23% | 49.95% | 51.25% | 53.67% | -21.09% | 57.28% | 49.56% | -19.30% | 15.72% | 24.57% | -21.43% | -38.82% | -171.47% | -69.00% | -63.17% | -992.59% | -617.07% | -330.95% | -157.14% | -307.69% |
Income Tax Expense | 1.25B | 1.25B | 2.08B | 1.58B | -204.00M | 2.34B | 8.89B | 3.61B | 3.55B | 2.80B | 1.15B | 1.04B | 861.95M | 1.02B | 876.36M | 723.25M | 655.04M | 551.75M | 347.88M | 207.05M | -95.53M | 1.30M | 4.14M | 1.20M | 900.00K | -36.60M | -36.20M | -29.40M | -9.80M | -8.00M | -8.40M | -3.70M | -1.60M |
Net Income | 5.67B | 4.59B | 6.23B | 89.00M | 5.39B | 5.46B | 4.63B | 13.50B | 18.11B | 12.10B | 3.07B | 2.59B | 2.80B | 2.90B | 2.64B | 2.01B | 1.62B | -1.19B | 813.91M | 449.37M | -72.00M | 72.10M | 52.27M | -56.78M | -66.50M | -56.10M | -28.00M | -21.70M | -27.40M | -25.70M | -14.10M | -4.50M | -4.00M |
Net Income Ratio | 20.89% | 16.83% | 22.80% | 0.36% | 23.99% | 24.65% | 17.73% | 44.43% | 55.48% | 48.62% | 27.45% | 26.71% | 33.43% | 36.50% | 37.59% | 37.69% | 38.19% | -39.32% | 40.13% | 33.92% | -8.30% | 15.45% | 22.36% | -29.03% | -39.35% | -172.09% | -70.00% | -64.97% | -1,014.81% | -626.83% | -335.71% | -160.71% | -307.69% |
EPS | 4.54 | 3.66 | 4.96 | 0.07 | 4.24 | 4.20 | 3.54 | 10.08 | 12.37 | 7.95 | 2.01 | 1.71 | 1.81 | 1.70 | 1.46 | 1.09 | 0.87 | -0.65 | 0.45 | 0.26 | -0.04 | 0.05 | 0.04 | -0.04 | -0.05 | -0.04 | -0.03 | -0.02 | -0.04 | -0.04 | -0.03 | -0.01 | -0.01 |
EPS Diluted | 4.50 | 3.64 | 4.93 | 0.07 | 4.22 | 4.17 | 3.51 | 9.94 | 11.91 | 7.35 | 1.81 | 1.64 | 1.78 | 1.66 | 1.41 | 1.05 | 0.84 | -0.65 | 0.43 | 0.25 | -0.04 | 0.04 | 0.03 | -0.04 | -0.05 | -0.04 | -0.03 | -0.02 | -0.04 | -0.04 | -0.03 | -0.01 | -0.01 |
Weighted Avg Shares Out | 1.25B | 1.26B | 1.26B | 1.26B | 1.27B | 1.30B | 1.31B | 1.34B | 1.46B | 1.52B | 1.53B | 1.51B | 1.55B | 1.71B | 1.81B | 1.84B | 1.86B | 1.84B | 1.82B | 1.73B | 1.61B | 1.56B | 1.52B | 1.46B | 1.37B | 1.31B | 1.04B | 889.15M | 680.77M | 595.94M | 512.73M | 360.00M | 304.76M |
Weighted Avg Shares Out (Dil) | 1.26B | 1.26B | 1.26B | 1.26B | 1.28B | 1.31B | 1.32B | 1.36B | 1.52B | 1.65B | 1.69B | 1.58B | 1.58B | 1.75B | 1.87B | 1.92B | 1.93B | 1.84B | 1.90B | 1.86B | 1.61B | 1.65B | 1.62B | 1.46B | 1.37B | 1.31B | 1.04B | 889.15M | 680.77M | 595.94M | 512.73M | 360.00M | 304.76M |
7 Defensive Stocks to Buy as Investors Seek Shelter
US FDA approves Gilead's liver disease drug
3 Stocks Retirees Should Absolutely Love
Analysts Cite Improved Investor Sentiment For Gilead, But Warn of Limited Growth at Current Stock Levels
Gilead Posts Solid Revenue in Q2
Gilead (GILD) Q2 Earnings Beat, Annual Profit Guidance Raised
Gilead Sciences, Inc. (GILD) Q2 2024 Earnings Call Transcript
Gilead (GILD) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
Gilead Sciences (GILD) Q2 Earnings and Revenues Beat Estimates
Gilead Eyes A Breakout After Second-Quarter Sales, Earnings Beat
Source: https://incomestatements.info
Category: Stock Reports